| Drug Name | Tresiba (degludec) |
|---|---|
| Drug Class |
Anti-diabetic
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Endocrine
|
| Risk |
The association of insulin degludec (Tresiba®) with the risk of mixing up two strengths |
| Dear Healthcare provider letter DHPC |
|